公开(公告)号：US11814432B2

公开(公告)日：2023-11-14

申请号：US16649426

申请日：2018-09-20

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  SANGAMO THERAPEUTICS FRANCE

发明人： Li Zhou ,  Tobias Abel ,  François Meyer ,  Megan Levings ,  Nicolas Dawson ,  Caroline Lamarche

IPC分类号： C07K16/28 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  A61K35/12

CPC分类号： C07K16/2833 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70575 ,  A61K2035/122 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

摘要： The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.

公开(公告)号：US20240067732A1

公开(公告)日：2024-02-29

申请号：US18475582

申请日：2023-09-27

申请人： THE UNIVERSITY OF BRITISH COLUMBIA ,  SANGAMO THERAPEUTICS FRANCE

发明人： Li Zhou ,  Tobias Abel ,  François Meyer ,  Megan Levings ,  Nicolas Dawson ,  Caroline Lamarche

IPC分类号： C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725

CPC分类号： C07K16/2833 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70575 ,  A61K2035/122

摘要： The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.

公开(公告)号：US11981739B2

公开(公告)日：2024-05-14

申请号：US17047232

申请日：2019-04-15

申请人： SANGAMO THERAPEUTICS FRANCE

发明人： Tobias Abel ,  Julie Gertner-Dardenne ,  François Meyer

IPC分类号： C07K14/705 ,  A61K35/17 ,  A61P17/00 ,  A61P29/00 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61P17/00 ,  A61P29/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C12N5/0637 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2510/00

摘要： The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.

公开(公告)号：US20210380704A1

公开(公告)日：2021-12-09

申请号：US17047232

申请日：2019-04-15

申请人： SANGAMO THERAPEUTICS FRANCE

发明人： Tobias Abel ,  Julie Gertner-Dardenne ,  François Meyer

IPC分类号： C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61K35/17 ,  C12N5/0783 ,  A61P29/00 ,  A61P17/00

摘要： The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.

公开(公告)号：US20210292389A1

公开(公告)日：2021-09-23

申请号：US17267410

申请日：2019-08-09

申请人： SANGAMO THERAPEUTICS FRANCE

发明人： Tobias Abel ,  David Fenard ,  Julie Gertner-Dardenne ,  François Meyer

IPC分类号： C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  A61K35/17 ,  A61P37/06

摘要： The present invention relates to a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof, and to an immune cell expressing said CAR. The present invention further relates to therapeutic methods comprising the administration of an immune cell expressing a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof.